Comparative risk of incident cancer in patients with inflammatory bowel disease with prior non-digestive malignancy according to immunomodulator: a multicentre …
F Poullenot, A Amiot, S Viennot… - Journal of Crohn's …, 2022 - academic.oup.com
Introduction Knowledge about the cancer risk when initiating a biologic in inflammatory
bowel disease [IBD] patients with prior malignancy remains scarce, especially for …
bowel disease [IBD] patients with prior malignancy remains scarce, especially for …
P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a …
F Poullenot, A Amiot, M Nachury… - Journal of Crohn's …, 2022 - academic.oup.com
Background Knowledge about the cancer risk when initiating a biologic in Inflammatory
Bowel Disease (IBD) patients with prior malignancy remains scarce especially for …
Bowel Disease (IBD) patients with prior malignancy remains scarce especially for …
[引用][C] Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a …
F Poullenot, A Amiot, M Nachury, S Viennot, R Altwegg… - 2022 - lilloa.univ-lille.fr
Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior
non-digestive malignancy according to immunomodulator: a multicenter cohort study. Toggle …
non-digestive malignancy according to immunomodulator: a multicenter cohort study. Toggle …
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre …
F Poullenot, A Amiot, M Nachury… - Journal of Crohn's …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Knowledge about the cancer risk when initiating a biologic in inflammatory
bowel disease [IBD] patients with prior malignancy remains scarce, especially for …
bowel disease [IBD] patients with prior malignancy remains scarce, especially for …
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre …
F Poullenot, A Amiot, M Nachury… - Journal of Crohn's …, 2022 - search.ebscohost.com
Introduction Knowledge about the cancer risk when initiating a biologic in inflammatory
bowel disease [IBD] patients with prior malignancy remains scarce, especially for …
bowel disease [IBD] patients with prior malignancy remains scarce, especially for …
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre …
F Poullenot, A Amiot, M Nachury, S Viennot… - Journal of Crohn's & …, 2022 - europepmc.org
Methods A multicentre retrospective study included consecutive IBD patients with prior non-
digestive malignancy. Inclusion date corresponded to the diagnosis of index malignancy …
digestive malignancy. Inclusion date corresponded to the diagnosis of index malignancy …
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre …
F Poullenot, A Amiot, M Nachury, S Viennot… - Journal of Crohn's and …, 2022 - hal.science
Introduction Knowledge about the cancer risk when initiating a biologic in inflammatory
bowel disease [IBD] patients with prior malignancy remains scarce, especially for …
bowel disease [IBD] patients with prior malignancy remains scarce, especially for …
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre …
F Poullenot, A Amiot, M Nachury… - Journal of Crohn's …, 2022 - u-picardie.hal.science
Introduction Knowledge about the cancer risk when initiating a biologic in inflammatory
bowel disease [IBD] patients with prior malignancy remains scarce, especially for …
bowel disease [IBD] patients with prior malignancy remains scarce, especially for …
[引用][C] Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a …
F Poullenot, A Amiot, M Nachury, S Viennot… - Journal of Crohn's and …, 2022 - hal.science
Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior
non-digestive malignancy according to immunomodulator: a multicenter cohort study - Archive …
non-digestive malignancy according to immunomodulator: a multicenter cohort study - Archive …
[引用][C] Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a …
F Poullenot, A Amiot, M Nachury… - Journal of Crohn's …, 2022 - u-picardie.hal.science
Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior
non-digestive malignancy according to immunomodulator: a multicenter cohort study - Université …
non-digestive malignancy according to immunomodulator: a multicenter cohort study - Université …